BiondVax announces a proposed public offer for outright subscription of US depositary shares


JERUSALEM, 23 December 2021 / PRNewswire / – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on the development, manufacture and commercialization of innovative products for the prevention and treatment of infectious diseases and other diseases, today announced its intention to offer its US depository shares (“ADS”) as part of a subscribed public offering.

As announced yesterday (Dec 22 2021), BiondVax has signed definitive agreements with the Max Planck Society (MPG), the parent organization of the Max Planck Institute for Biophysical Chemistry, and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development and commercialization of innovative nanometric COVID-19 antibodies (NanoAbs). These NanoAbs have shown in vitro neutralization of all COVID-19 variants of concern, including Delta, and based on in silico studies, Omicron, at dose levels significantly lower than existing antibody treatments. These agreements are part of a larger collaboration, which should be signed in January 2022, covering the development and commercialization of NanoAbs for several other disease indications with large market sizes that take advantage of their unique binding affinity, high temperature stability and potential for more efficient routes of administration and more practical.

The Company intends to use the net proceeds of this offering for the advancement of its NanoAbs development program as well as for general corporate objectives, including, but not limited to, the fund. turnover, research and development activities, regulatory matters, capital investment or other related purposes. . It may also use a portion of any net proceeds to license, invest in or acquire any businesses, assets or technologies that it deems complementary to its business purpose, although it has no current commitment or agreement to. this regard. The Offer is subject to market conditions, and there can be no assurance as to whether or when the Offer may be made, or as to the size or actual terms of the Offer.

Aegis Capital Corp. acts as the only accounting manager of the offer.

This offering is made pursuant to a current registration statement on Form F-3 (No. 333-240189) previously filed with the United States Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on Aug 10, 2020. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus can be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, New York State 10019, by email to [email protected], or by phone at (212) 813-1010. Before investing in this offering, interested parties should read the entire Prospectus Supplement and accompanying Prospectus and other documents the Company has filed with the SEC which are incorporated by reference in this Prospectus Supplement. and the accompanying prospectus, which provide more information about the Company and this offer.

This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BiondVax:
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on the development, manufacture and commercialization of innovative products for the prevention and treatment of infectious and other diseases. Since its inception, the company has completed eight clinical trials, including a Phase 3 trial in seven countries, with 12,400 participants, of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceuticals. With highly experienced leadership in the pharmaceutical industry, BiondVax aims to develop a pipeline of diversified and commercially viable products and platforms, starting with an innovative pipeline of nanoscale antibodies (NanoAb). For more information, please visit www.biondvax.com.

Forward-looking statements

The Private Securities Litigation Reform Act of 1995 provides a safe haven for forward-looking statements made by or on our behalf. This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding BiondVax’s intention to conduct an offer and sale of securities, the ability to complete the offer and the intended use of the proceeds of the offer. Any statement that is not historical in nature is a forward-looking statement and can be identified by the use of words and phrases such as “expects”, “anticipates”, “believes”, “will”, “in”. will likely result “,” will continue “,” considering “,” potential “,” promising “and similar expressions. These statements are based on the current expectations and beliefs of management and are subject to a number of risks, risks and assumptions. uncertainties and assumptions that could cause actual results to differ materially from those described in forward-looking statements, including the risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. BiondVax assumes no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described here should not be taken as a complete list.

SOURCE BiondVax Pharmaceuticals Ltd.


Comments are closed.